en · de · es · pt
assay-notes.peptides6608.com › Wiki › Dihexa Chemical Identity And Origin — Quick Reference

Dihexa Chemical Identity And Origin — Quick Reference

By Editorial Desk · published 2026-07-20 · last reviewed 2026-08-01 · Wiki

The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Dihexa Chemical Identity and Origin

The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.

Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.

Chemical Identity and Research Background

Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.

Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.

Dihexa at a glance

PropertyValueNotes
Common nameDihexaShorthand used in research literature and supplier catalogs.
CAS Registry Number1401708-83-5Identifier assigned to the synthetic peptide.
Molecular formulaC27H44N4O5Reported formula; verify with a certificate of analysis.
AppearanceWhite to off-white powderTypical form for lyophilized research peptides.
Typical storage−20 °C or below, desiccatedCommon condition for peptide stability.

Preclinical Research and Regulation

Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.

Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.

Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.

Related pages on this site

Mechanism And Laboratory Characterization

The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.

Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.

Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.

Mechanism and Research Status

The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.

Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.

Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.

Background from the literature

1932) journalist-op-ed column writer for The Guardian, New Statesman, Financial Times, Time; Labour Party politician and former Member of Parliament; appointed Labour life peer with the title of Baron Dubs, of Battersea in the London Borough of Wandsworth; was chair of Broadcasting Standards Commission (Ofcom) and deputy chair of Independent Television Commission; chair of Liberty, trustee of Action Aid, trustee of the Immigration Advisory Service; vice president of Fabian Society; patron of Humanists UK, a patron of Refugee Support Group; treasurer of the All-Party Parliamentary Humanist Group. Matthew Engel (born 11 June 1951); writer, author of over ten books, editor, journalist for The Jewish Chronicle, The Guardian, Daily Mail, The Independent, The Telegraph, 1843, Financial Times, New Statesman, The Times Literary Supplement; of Polish Jewish ancestry. Richard Ferrer; journalist and editor of Jewish News; sub-editor at the Daily Mirror; written for the Daily Telegraph, The Times, Algemeiner, The Times of Israel and the Independent; regular contributor to programmes on BBC Radio 4. Lord Baron Daniel Finkelstein,(born 30 August 1962); journalist and politician; writes for Jewish Chronicle; former executive editor of The Times.; former chairman of Policy Exchange; chair of the think tank Onward; made a member of the House of Lords in August 2013, sitting as a Conservative.

Croton lechleri is a species of flowering plant in the spurge family, Euphorbiaceae, that is native to northwestern South America. It is commonly known as sangre de grado (sic, Peruvian Spanish), sangre de drago (Ecuadorian Spanish) or sangre de grada (sic, Bolivian Spanish). They refer to this tree's (and several related species') thick red latex. The latex has medicinal properties, and is used by local peoples as a liquid bandage, applied to seal wounds, as it dries quickly to form a protective skin-like barrier. Its use by native people has led to scientific study and observation of its in vitro antioxidant activity as well as both mutagenic and antimutagenic behavior. The latex also contains a number of chemicals, including taspine. Oligomeric proanthocyanidins, another kind of chemical contained in the latex, have been investigated for the treatment of HIV-associated diarrhea under the name crofelemer. In January 2013, crofelemer, under the trade name Mytesi, was approved by the FDA for the treatment of non-infectious diarrhea in HIV+ patients.

The Great French Wine Blight was a severe blight of the mid-19th century that destroyed many of the vineyards in France and laid waste to the wine industry. It was caused by an insect that originated in North America and was carried across the Atlantic in the late 1850s. The actual genus of the insect is still debated, although it is largely considered to have been a species of Daktulosphaira vitifoliae, commonly known as grape phylloxera. While France is considered to have been worst affected, the blight also did a great deal of damage to vineyards in other European countries. How Phylloxera was introduced to Europe remains debated: American vines had been taken to Europe many times before, for reasons including experimentation and trials in grafting, without consideration of the possibility of the introduction of pestilence. While the Phylloxera was thought to have arrived around 1858, it was first recorded in France in 1863, in the former province of Languedoc. It is argued by some that the introduction of such pests as phylloxera was only a problem after the invention of steamships, which allowed a faster journey across the ocean, and consequently allowed pests such as the Phylloxera to survive the trip. Eventually, following Jules-Émile Planchon's discovery of the Phylloxera as the cause of the blight, and Charles Valentine Riley's confirmation of Planchon's theory, Leo Laliman and Gaston Bazille, two French wine growers, proposed that the European vines be grafted to the resistant American rootstock that were not susceptible to the Phylloxera.

Sources: en.wikipedia.org

Further detail

Unable to afford the TCB Band, the group featured guitarists Jock Bartley and Larry Coryell, Neil Flanz on pedal steel, bassist Kyle Tullis, and drummer N. D. Smart. The touring party also included Parsons' new wife, Gretchen Parsons, who was envious of Harris and her young daughter. Coordinating the spectacle as road manager was Phil Kaufman, who had served time with Charles Manson on Terminal Island but who ensured that the performer stayed clear of drugs and limited his alcohol intake during shows. At first, the band was under-rehearsed and played poorly; however, they improved with steady gigging and received rapturous responses at several counter-cultural venues, including Armadillo World Headquarters in Austin, Max's Kansas City in New York City, and Liberty Hall in Houston, where Neil Young and Linda Ronstadt sat in for a filmed performance. Nevertheless, the tour failed to galvanize sales of GP, which never charted in the Billboard 200. For his next and final album, 1974's posthumously released Grievous Angel, Parsons used Harris and members of the TCB Band. The record received more enthusiastic reviews than GP. Although Parsons only contributed two new songs to the album ("In My Hour of Darkness" and "Return of the Grievous Angel"), he was reportedly enthusiastic with his new sound and seemed to have finally adopted a diligent mindset to his musical career, limiting his intake of alcohol and opiates during most of the sessions. Grievous Angel peaked at number 195 on the Billboard chart.

Historically, terminal elimination half-lives were considered very long, 40–50 days for Hydroxychloroquine as compared to up to 60 days for Chloroquine. More recent studies suggest a shorter half-life of about 5 days. A long Hydroxychloroquine half-life is attributed to extensive tissue uptake rather than to an intrinsic inability to clear the drug. The expected delay in the attainment of steady-state concentrations (3–4 months) may be in part responsible for the slow therapeutic response observed with Hydroxychloroquine. Agents may be used in combination, however, people may experience greater side effects. Methotrexate is the most important and useful DMARD and is usually the first treatment. A combined approach with methotrexate and biologics improves ACR50, HAQ scores and RA remission rates. This benefit from the combination of methotrexate with biologics occurs both when this combination is the initial treatment and when drugs are prescribed in a sequential or step-up manner. Triple therapy consisting of methotrexate, sulfasalazine and hydroxychloroquine may also effectively control disease activity. Adverse effects should be monitored regularly with toxicity including gastrointestinal, hematologic, pulmonary, and hepatic. Side effects such as nausea, vomiting or abdominal pain can be reduced by taking folic acid. Rituximab combined with methotrexate appears to be more effective in improving symptoms compared to methotrexate alone. Rituximab works by decreasing levels of B-cells (an immune cell that is involved in inflammation).

=== Range === The conversion efficiency is essentially 100% from minimum detectable levels up to a flow of CO or CO2 at the detector of about 5×10−5g/s. These represent a detection limit of about 200 ppb and a maximum concentration of about 10% in a 0.5mL sample. Both values are dependent upon peak width.

=== West Asia === Documentation of the use of saffron over the span of 3,500 years has been uncovered. Saffron -based pigments have indeed been found in 50,000-year-old depictions of prehistoric places in northwest Iran. The Sumerians later used wild-growing saffron in their remedies and magical potions. It was also known in ancient Egypt, as indicated by a 2000 BC papyrus. Saffron was an article of long-distance trade before the Minoan palace culture's 2nd millennium BC peak. Ancient Persians cultivated Persian saffron (Crocus sativus var. haussknechtii now called Crocus haussknechtii by botanists) in Derbent, Isfahan, and Khorasan by the 10th century BC. At such sites, saffron threads were woven into textiles, ritually offered to divinities, and used in dyes, perfumes, medicines, and body washes. Saffron threads would thus be scattered across beds and mixed into hot teas as a curative for bouts of melancholy. Non-Persians also feared the Persians' usage of saffron as a drugging agent and aphrodisiac. Saffron is featured in trade lists from Mari, Syria, is described in a 7th-century BC Assyrian botanical reference compiled under Ashurbanipal, and is listed among other aromatic plants in the Hebrew Bible, in Song of Songs 4:14. During his Asian campaigns, Alexander the Great used Persian saffron in his infusions, rice, and baths as a curative for battle wounds. Alexander's troops imitated the practice from the Persians and brought saffron-bathing to Greece.

Sources: en.wikipedia.org

Supporting material

The Apex bank stated that all transactions conducted through correspondent banking relationships shall be managed with a risk-based approach and Know Your Correspondent procedures, this is to ascertain whether the bank or financial institution is regulated by a money laundering prevention body. The correspondent is to take action to identify the customer. The CBN also released a guidance note named; Anti–money Laundering/combating the financing of terrorism (AML/CFT) for OFIs. The CBN Financial Policy and Regulation Director Chibuzo Efobi mentioned that the guidance note would enable the sub-sector to identify, assess and minimize the risks of terrorist financing and money laundering. He also said that this Guidance note would identify risk management procedures that would lessen the vulnerability of financial institutions to Money laundering schemes.

=== Psychotropic effects === Bromantane is described primarily as a mild stimulant and anxiolytic. It is also said to possess anti-asthenic properties. Bromantane is reported to improve physical and mental performance, hence it could be considered a performance-enhancing drug. Bromantane has been found to lower the levels of pro-inflammatory cytokines IL-6, IL-17 and IL-4 and to normalize behavior in animal models of depression, and may possess clinical efficacy as an antidepressant. It has also been found to increase sexual receptivity and proceptivity in rats of both sexes, which was attributed to its dopaminergic actions. It has been proposed that bromantane may suppress prolactin levels by virtue of its dopaminergic properties as well. Bromantane has been found to "agonize" amphetamine-induced stereotypies in vivo, suggesting that it might potentiate certain effects of other stimulants. The stimulant effects of bromantane onset gradually within 1.5–2 hours and last for 8–12 hours when taken orally.

Finally, he had design roles on many ZeniMax Media-owned games: Wolfenstein: The New Order (2014), Fallout 4 (2015), Doom (2016), Dishonored 2 (2016), The Elder Scrolls: Legends (2017), and Prey (2017).

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.

Where does dihexa come from?

It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.

Is dihexa the same as angiotensin IV?

No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.

What is dihexa?

Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.

Network